Clinical Trial: NCT06848348
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | Dogwood Therapeutics Inc. |
| Information Provided By: | Dogwood Therapeutics Inc. |
| Last Update Posted: | 2026-09-16 |
Study Overview
Brief Summary
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extension phase, where available, in which all subjects will receive Halneuron.
Official Title
A Randomized, Double-Blind, Placebo Controlled, Multicenter Study With Optional Open-Label Extension to Evaluate the Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Conditions
Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
Intervention / Treatment
- Drug: Halneuron
- Drug: Placebo
- Drug: Halneuron (Open Label Extension)
Other Study ID Numbers
- HAL-CINP-203
Start Date (Actual)
2025-02-21
Primary Completion Date (Estimated)
2026-12
Study Completion Date (Estimated)
2026-12
Enrollment (Estimated)
240
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Dogwood Therapeutics Inc. |
| Information Provided By: | Dogwood Therapeutics Inc. |
| Last Update Posted: | 2026-09-16 |
Study Overview
Brief Summary
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extension phase, where available, in which all subjects will receive Halneuron.
Official Title
A Randomized, Double-Blind, Placebo Controlled, Multicenter Study With Optional Open-Label Extension to Evaluate the Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
Conditions
Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy, Chemotherapy Induced Pain
Intervention / Treatment
- Drug: Halneuron
- Drug: Placebo
- Drug: Halneuron (Open Label Extension)
Other Study ID Numbers
- HAL-CINP-203
Start Date (Actual)
2025-02-21
Primary Completion Date (Estimated)
2026-12
Study Completion Date (Estimated)
2026-12
Enrollment (Estimated)
240
Study Type
Interventional
Phase
Phase 2